HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

FTO genotype and weight loss: systematic review and meta-analysis of 9563 individual participant data from eight randomised controlled trials.

AbstractOBJECTIVE:
 To assess the effect of the FTO genotype on weight loss after dietary, physical activity, or drug based interventions in randomised controlled trials.
DESIGN:
 Systematic review and random effects meta-analysis of individual participant data from randomised controlled trials.
DATA SOURCES:
 Ovid Medline, Scopus, Embase, and Cochrane from inception to November 2015.
ELIGIBILITY CRITERIA FOR STUDY SELECTION:
 Randomised controlled trials in overweight or obese adults reporting reduction in body mass index, body weight, or waist circumference by FTO genotype (rs9939609 or a proxy) after dietary, physical activity, or drug based interventions. Gene by treatment interaction models were fitted to individual participant data from all studies included in this review, using allele dose coding for genetic effects and a common set of covariates. Study level interactions were combined using random effect models. Metaregression and subgroup analysis were used to assess sources of study heterogeneity.
RESULTS:
 We identified eight eligible randomised controlled trials for the systematic review and meta-analysis (n=9563). Overall, differential changes in body mass index, body weight, and waist circumference in response to weight loss intervention were not significantly different between FTO genotypes. Sensitivity analyses indicated that differential changes in body mass index, body weight, and waist circumference by FTO genotype did not differ by intervention type, intervention length, ethnicity, sample size, sex, and baseline body mass index and age category.
CONCLUSIONS:
 We have observed that carriage of the FTO minor allele was not associated with differential change in adiposity after weight loss interventions. These findings show that individuals carrying the minor allele respond equally well to dietary, physical activity, or drug based weight loss interventions and thus genetic predisposition to obesity associated with the FTO minor allele can be at least partly counteracted through such interventions.
SYSTEMATIC REVIEW REGISTRATION:
 PROSPERO CRD42015015969.
AuthorsKatherine M Livingstone, Carlos Celis-Morales, George D Papandonatos, Bahar Erar, Jose C Florez, Kathleen A Jablonski, Cristina Razquin, Amelia Marti, Yoriko Heianza, Tao Huang, Frank M Sacks, Mathilde Svendstrup, Xuemei Sui, Timothy S Church, Tiina Jääskeläinen, Jaana Lindström, Jaakko Tuomilehto, Matti Uusitupa, Tuomo Rankinen, Wim H M Saris, Torben Hansen, Oluf Pedersen, Arne Astrup, Thorkild I A Sørensen, Lu Qi, George A Bray, Miguel A Martinez-Gonzalez, J Alfredo Martinez, Paul W Franks, Jeanne M McCaffery, Jose Lara, John C Mathers
JournalBMJ (Clinical research ed.) (BMJ) Vol. 354 Pg. i4707 (Sep 20 2016) ISSN: 1756-1833 [Electronic] England
PMID27650503 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
CopyrightPublished by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Chemical References
  • Alpha-Ketoglutarate-Dependent Dioxygenase FTO
  • FTO protein, human
Topics
  • Adiposity (genetics)
  • Alleles
  • Alpha-Ketoglutarate-Dependent Dioxygenase FTO (genetics)
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Obesity (diet therapy, genetics)
  • Randomized Controlled Trials as Topic
  • Weight Loss (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: